BioNTech's COVID-19 vaccine, BNT162, is currently going through Phase2b/3 clinical trials. The company set a regulatory review as soon as October 2020. Many countries have already begun to have talks with BioNTech about getting millions of doses of BNT162. These countries include the US and Japan. If all goes well they plan to have 1.3 billion doses by the end of 2021.